SCHEMBL4069294

SCHEMBL4069294

N#Cc1cc(F)ccc1-c1ccc2cc(S(=O)(=O)c3ccccc3)ccc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.45
HTR2A P28223 5/20 0.41
HTR2C P28335 3/20 0.41
KCNH2 Q12809 3/20 0.41
NR3C1 P04150 1/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
STAT3 P40763 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38
TUBA3E Q6PEY2 1/20 0.38
TUBA1A Q71U36 1/20 0.38
TUBA1C Q9BQE3 1/20 0.38
TUBB6 Q9BUF5 1/20 0.38
TUBB2B Q9BVA1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073507 0.80 HTR2A (0.44) ABL1HTR2AHTR2CKCNH2TUBB4A
SCHEMBL4076387 0.79 CA2 (0.50) HTR2AHTR2CKCNH2MEN1KMT2A
SCHEMBL4068571 0.78 HTR2A (0.44) HTR2AHTR2CKCNH2PTGS2PTGDR2
SCHEMBL4069615 0.78 ABL1 (0.45) ABL1NR3C1MEN1KMT2ASTS
SCHEMBL4069576 0.75 HSD11B1 (0.46) HTR2AHTR2CKCNH2NR3C1MEN1
SCHEMBL4780146 0.73 ADORA1 (0.46) MEN1KMT2A
SCHEMBL3164357 0.70 HTR2A (0.70) HTR2AHTR2CKCNH2MEN1KMT2A
SCHEMBL3164364 0.70 HTR2A (0.70) HTR2AHTR2CKCNH2MEN1KMT2A
SCHEMBL5523220 0.70 CYP1A2 (0.50) HTR2AHTR2CKCNH2
SCHEMBL11121243 0.69 HTR6 (0.52) HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592456-B2 Arylsulfonylnaphthalene derivatives as 5HT2A antagonists MERCK SHARP & DOHME LIMITED (GB) 2009-09-22 US disclosed
EP-1824817-B1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME (GB) 2009-02-04 EP disclosed
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists MERCK SHARPE & DOHME LIMITED (GB) 2007-12-06 US disclosed
CN-101068776-A As 5HT2AArylsulfonyl naphthalene derivatives as antagonists MERCH SHARP & DOHME LTD (GB) 2007-11-07 CN disclosed
EP-1824817-A1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-08-29 EP disclosed
WO-2006059149-A1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists HTR2A, HTR2C, HTR1A ABL1 1524/4885HTR2A 1/4885HTR2C 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.